Current CAPS guidelines recommend screening those with at least two affected FDRs; patients with Peutz-Jeghers syndrome (PJS); and P16, BRCA2 and hereditary non-polyposis colorectal cancer (HNPCC) mutation carriers with ≥1 affected FDR [7]. Here, BRCA2 is linked to Peutz-Jeghers syndrome.